Startup Scout 15 Dec 2017 Czech this Biotech Out! Bioinova Develops Stem Cell Therapies This week, we are in Prague to visit Bioinova. This biotech develops cell therapies for a wide range of indications, from broken bones to autoimmune diseases. Mission: From bone marrow and adipose (fat) tissue, Bioinova develops stem cell products that can be used for orthopedic, ophthalmological, neurological, and autoimmune indications, as well as to aid wound healing. […] December 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 The FDA Fast Tracks Therapy for Rare Disease Causing Copper Accumulation The FDA is speeding up the process for regulatory approval of WTX101, a therapy for Wilson’s disease that could significantly improve the standard of care. Wilson Therapeutics, in Stockholm, has convinced the FDA to include its drug WTX101 (bis-choline tetrathiomolybdate) in its Fast Track program. This move will speed up the approval of the drug, […] December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech Gilead has joined a growing list of powerful investors that want to help Hookipa Biotech develop its vaccine technology by participating in its Series C fundraising. Hookipa Biotech, one of October’s biotechs of the week, develops vaccines for cancer and infectious diseases. Its pipeline includes two platforms: Vaxwave and TheraT, which are targeted at cytomegalovirus infections and […] December 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies? Researchers from the University of Zurich have determined the structure of a chloride channel, which could be a target for new drugs to treat cystic fibrosis. Researchers at the University of Zurich have found a new target for future cystic fibrosis treatments. The study, published in Nature, has uncovered the structure of a protein that could help to […] December 14, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 14 Dec 2017 New Biotech in Oxford Takes on Arthritis of the Spine Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […] December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma GeneQuine’s gene therapy for osteoarthritis in the knee has been acquired by US pharma company Flexion Therapeutics for up to $64M. GeneQuine is developing a gene therapy for the treatment of osteoarthritis. It uses helper-dependent adenoviruses, which provide long-term expression, a higher packaging capacity, reduced immunogenicity and they do not integrate into the host genome. It seems like yesterday […] December 14, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […] December 14, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Dec 2017 10 Biotechnology Books To Read These Winter Holidays Here is a list of some of the best biotechnology books to add to your 2018 to-read list and get up to date with the ins and outs of the biotech world. Winter is here, at least for those of us living in the Northern hemisphere. I am personally looking forward to warm evenings at […] December 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of the year, Regeneron and Sanofi are still committed to pushing through a number of candidates. One of these, cemiplimab, is a programmed cell death protein-1 (PD-1) checkpoint […] December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has proved to be effective at treating cancer in patients for whom scarce hope was left. Yet pricing is still a big concern. Companies like Cellectis are trying […] December 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018 CRISPR Therapeutics and Vertex Pharmaceuticals are taking action to start a first clinical trial with CRISPR/Cas9 in Europe in 2018. The blood disorder β-thalassemia could soon be the first human disease to be treated using CRISPR/Cas9 technology in Europe. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have announced the first candidate from their collaboration that will go […] December 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 New Belgian Biotech Secures €27M Series A to Develop Peptide Antibiotics Aelin Therapeutics will develop its Pept-in technology, which could hold the answer to the growing antibiotics resistance crisis. Aelin Therapeutics is a Belgian biotherapeutics company that is hoping to pioneer Pept-in, protein knockdown drugs that could revolutionize the antibiotics field and open up previously undruggable targets. The company was founded by VIB and partner universities […] December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email